Pharmaceuticals

Global Cyramza (Ramucirumab) Market Set To Expand To $6.29 Billion By 2030 At 9.7% CAGR

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Cyramza (Ramucirumab) Market Grow Between 2026 And 2030?

The cyramza (ramucirumab) market has experienced significant expansion over recent years. Its value is projected to increase from $1.31 million in 2025 to $1.4 million in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. Historically, this growth can be attributed to factors such as its approval for gastric and colorectal cancers, the rising global burden of cancer, the clinical success of VEGFR inhibitors, widespread adoption in hospital oncology, and the limited availability of late-stage treatment options.

The market for cyramza (ramucirumab) is projected to experience substantial expansion over the upcoming years, with its size anticipated to reach $1.79 million by 2030, growing at a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period is primarily attributed to factors such as the increasing incidence of solid tumors, its expansion into new oncology indications, the general growth of targeted cancer therapies, rising oncology healthcare spending, and improved diagnostic rates. Furthermore, significant trends shaping this period include the growing utilization of anti-angiogenic therapies, its application across multiple cancer indications, its combination use with chemotherapy, an increasing demand in advanced-stage cancers, and its administration predominantly in hospital-based oncology settings.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19894&type=smp

What Key Factors Are Affecting The Cyramza (Ramucirumab) Market Demand?

The increasing occurrence of cancer is projected to boost the expansion of the Cyramza (ramucirumab) market. Cancer is defined as a collection of diseases marked by uncontrolled cell multiplication and dissemination throughout the body. The growth in cancer cases stems from elements such as an aging population, various lifestyle choices, environmental exposures, advancements in detection methods, and genetic predispositions. Cyramza (ramucirumab) functions in cancer therapy by targeting and hindering the vascular endothelial growth factor receptor 2 (VEGFR-2), which assists in preventing the development of tumor blood vessels and decelerating cancer’s progression. For example, a report from the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics on Australia’s health and welfare, published in August 2024, indicated that by 2034, Australia is anticipated to experience roughly 209,000 new cancer diagnoses. This represents a substantial rise from the estimated 169,000 cases predicted for 2024, reflecting the influence of an expanding population and increasing cancer rates. Furthermore, in 2024, cancer is expected to be responsible for approximately 3 out of every 10 deaths within the country. Consequently, the escalating incidence of cancer is propelling the growth of the Cyramza (ramucirumab) market.

How Are Segments Identified Within The Cyramza (Ramucirumab) Market Segment Framework?

The cyramza (ramucirumab) market covered in this report is segmented –

1) By Type: 100mg/Box, 500mg/Box

2) By Application: Advanced Gastric Cancer, GEJ Adenocarcinoma, Non-small Cell Lung Carcinoma, Metastatic Colorectal Cancer (mCRC), Hepatocellular Carcinoma (HCC)

3) By End-User: Hospitals, Cancer Treatment Centers, Ambulatory Surgical Centers, Research Institutes

Who Are The Companies Competing Within The Cyramza (Ramucirumab) Market?

Major companies operating in the cyramza (ramucirumab) market are Eli Lilly and Company

Get The Full Cyramza (Ramucirumab) Market Report:

https://www.thebusinessresearchcompany.com/report/cyramza-ramucirumab-global-market-report

Which Geographic Region Dominates The Cyramza (Ramucirumab) Market?

North America was the largest region in the cyramza (ramucirumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyramza (ramucirumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cyramza (Ramucirumab) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cyramza-ramucirumab-global-market-report

Browse Through More Reports Similar to the Global Cyramza (Ramucirumab) Market 2026, By The Business Research Company

Ranibizumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Cyclohexylbenzene Market Report 2026

https://www.thebusinessresearchcompany.com/report/cyclohexylbenzene-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795